Biodesix Announces First Quarter 2021 Results
May 11, 2021First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020
Announced Plans to Launch Two New Diagnostic Tests – SARS-CoV-2 Neutralization Antibody Detection Test and Next Generation Sequencing Test
BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter ended March 31, 2021 and provided a corporate update.
“We were pleased with our strong operating and financial performance in the first quarter and believe we are off to a solid start in 2021,” said Scott Hutton, Chief Executive Officer. “We are encouraged by the trends in our core lung diagnostic testing. Additionally, Biodesix continues to innovate as demonstrated through our announcement of two new products and we are well-positioned for the future.”
First Quarter 2021 Financial Results
- Successfully secured additional liquidity and deferred principal repayments through February 2024 by closing a new $30.0 million term loan and retiring the prior term loan for $25.9 million;
- Total revenue of $28.9 million, an increase of 466% over first quarter 2020 and 7% over fourth quarter 2020;
- COVID-19 testing revenue of $23.2 million, an increase of 8% over fourth quarter 2020;
- Lung diagnostic revenue of $4.0 million, representing continued recovery and growth of 10% over first quarter 2020 and 8% over fourth quarter 2020;
- Services revenue of $1.7 million, an increase of 12% over first quarter 2020 and 12% decline over fourth quarter 2020;
- Gross profit of $10.6 million and gross margin percentage of 37%, both aligned with management expectations, primarily as a result of growth in COVID-19 testing;
- Operating expenses (excluding direct costs and expenses) of $16.2 million, which includes an investment in the planned expansion of our salesforce, increased 36% over first quarter 2020 and 8% over fourth quarter 2020;
- Non-cash stock compensation expense of $1.8 million, $0 and $3.7 million recognized during first quarter 2021, first quarter 2020 and fourth quarter 2020, respectively; and
- Net loss of $7.0 million, an improvement of 28% over first quarter of 2020 and a 54% increase over fourth quarter 2020.
Business Highlights
Biodesix continues to make significant progress in lung diagnostics testing, including the addition of a new test to the lung cancer testing portfolio as well as new data that continues to support the value and utility of the Biodesix lung diagnostics portfolio. As a result of on-going progress, the Company was pleased to announce the following:
- Plans to add a blood-based 52-gene next generation sequencing (NGS) test to the portfolio were announced in April 2021. The NGS test has unprecedented turnaround time of only 72-hours, according to data presented in a recent publication in Diagnostics. The NGS test will complement the improved 36-hour turnaround time that the GeneStrat® ddPCR and VeriStrat® tests currently offer, providing expanded coverage of 52-genes and broader molecular markers. The test will be used for advanced, late-stage, or recurrent cancer mutation detection in non-small cell lung cancer (NSCLC) and is expected to begin to be offered to physicians in the first half of 2022.
- The issuance of two U.S. patents in April 2021 that enhance the Company’s ability to develop blood-based immunotherapy and other pipeline testing strategies for cancer patients.
- Presentation of data from three studies at the American Association for Cancer Research (AACR) Annual Meeting in April 2021, including data from VeriStrat® and the Primary Immune Response (PIR) test that further demonstrate the utility of protein biomarker data from blood-based proteomic testing to support targeted and immunotherapy treatment strategies for NSCLC patients.
Beyond advancements in the lung diagnostic portfolio, the Company continued to expand and progress its partnerships and services related to COVID-19 testing, including the following:
- In April 2021, announced a partnership with GenScript Biotech to conduct performance verification of the cPassTM SARS-CoV-2 Neutralization Antibody Detection test in our laboratory, with expected commercial launch in mid-year 2021. The test is the first and only surrogate neutralizing antibody test with FDA Emergency Use Authorization (EUA) to date and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or previous SARS-CoV-2 infection.
- In February 2021, announced a partnership with the Chicago Public Schools to provide antigen and Droplet Digital PCR (ddPCR)™ testing for Chicago Public School teachers and staff.
- In January 2021, collaborated with the Purdue University Protect Purdue Health Center, to test students taking classes on the West Lafayette, Indiana Campus living off-campus during the Spring 2021 semester.
Conference call and webcast information
Management will host an investor conference call and webcast today, May 11, 2021 at 4:30 p.m. Eastern Time.
|
Investor dial-in (domestic): |
833-665-0678 |
|
|
Investor dial-in (international): |
929-517-0173 |
|
|
Conference ID: |
4089648 |
|
|
Webcast: |
An archived replay of the webcast will be available on the Company’s website for a period of 90 days.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 16, 2021. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
|
Biodesix, Inc. Condensed Balance Sheets (unaudited) (in thousands) |
||||||||
|
|
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
|
Assets |
|
|||||||
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
55,329 |
|
|
$ |
62,126 |
|
|
Accounts receivable, net |
|
|
18,367 |
|
|
|
15,304 |
|
|
Other current assets |
|
|
7,548 |
|
|
|
8,710 |
|
|
Total current assets |
|
|
81,244 |
|
|
|
86,140 |
|
|
Non-current assets |
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
3,387 |
|
|
|
3,178 |
|
|
Intangible assets, net |
|
|
12,821 |
|
|
|
13,260 |
|
|
Other long-term assets |
|
|
3,003 |
|
|
|
3,461 |
|
|
Goodwill |
|
|
15,031 |
|
|
|
15,031 |
|
|
Total non-current assets |
|
|
34,242 |
|
|
|
34,930 |
|
|
Total assets |
|
$ |
115,486 |
|
|
$ |
121,070 |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|||||||
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
3,747 |
|
|
$ |
8,964 |
|
|
Accrued liabilities |
|
|
7,262 |
|
|
|
7,789 |
|
|
Deferred revenue |
|
|
2,408 |
|
|
|
3,532 |
|
|
Current portion of notes payable |
|
|
2,707 |
|
|
|
11,840 |
|
|
Total current liabilities |
|
|
16,124 |
|
|
|
32,125 |
|
|
Non-current liabilities |
|
|
|
|
|
|
|
|
|
Long-term notes payable |
|
|
30,328 |
|
|
|
15,926 |
|
|
Contingent consideration |
|
|
30,915 |
|
|
|
29,932 |
|
|
Other long-term liabilities |
|
|
1,687 |
|
|
|
1,921 |
|
|
Total non-current liabilities |
|
|
62,930 |
|
|
|
47,779 |
|
|
Total liabilities |
|
|
79,054 |
|
|
|
79,904 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2021 and 2020) shares issued and outstanding |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value, 200,000,000 shares authorized; 26,785,431 (2021) and 26,561,504 (2020) shares issued and outstanding |
|
|
27 |
|
|
|
27 |
|
|
Additional paid-in capital |
|
|
302,180 |
|
|
|
299,953 |
|
|
Accumulated deficit |
|
|
(265,775 |
) |
|
|
(258,814 |
) |
|
Total stockholders’ equity |
|
|
36,432 |
|
|
|
41,166 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
115,486 |
|
|
$ |
121,070 |
|
|
Biodesix, Inc. Condensed Statements of Operations (unaudited) (in thousands, except share data) |
||||||||
|
|
|
Three Months Ended |
|
|||||
|
|
|
March 31, 2021 |
|
|
March 31, 2020 |
|
||
|
Revenues |
|
|
|
|
|
|
|
|
|
COVID-19 |
|
$ |
23,232 |
|
|
$ |
— |
|
|
Lung diagnostic |
|
|
3,963 |
|
|
|
3,603 |
|
|
Diagnostic testing revenue |
|
|
27,195 |
|
|
|
3,603 |
|
|
Biopharma services |
|
|
1,671 |
|
|
|
1,493 |
|
|
Total revenues |
|
|
28,866 |
|
|
|
5,096 |
|
|
Direct costs and expenses |
|
|
18,218 |
|
|
|
1,581 |
|
|
Research and development |
|
|
3,321 |
|
|
|
2,900 |
|
|
Sales, marketing, general and administrative |
|
|
11,927 |
|
|
|
8,080 |
|
|
Change in fair value of contingent consideration |
|
|
983 |
|
|
|
957 |
|
|
Total operating expenses |
|
|
34,449 |
|
|
|
13,518 |
|
|
Loss from operations |
|
|
(5,583 |
) |
|
|
(8,422 |
) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(651 |
) |
|
|
(1,457 |
) |
|
Change in fair value of warrant liability |
|
|
— |
|
|
|
51 |
|
|
Loss on debt extinguishment |
|
|
(728 |
) |
|
|
— |
|
|
Other income, net |
|
|
1 |
|
|
|
123 |
|
|
Total other expense |
|
|
(1,378 |
) |
|
|
(1,283 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(6,961 |
) |
|
$ |
(9,705 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.26 |
) |
|
$ |
(37.18 |
) |
|
Weighted-average shares outstanding, basic and diluted |
|
|
26,604 |
|
|
|
261 |
|
Contacts
Media:
Bobbi Coffin
[email protected]
(303) 892-3203
Investors:
Chris Brinzey
[email protected]
(339) 970-2843